Esquivel M, Cussenot F, Ogilvie R I, East D S, Shaw D H
Br J Clin Pharmacol. 1984 Oct;18(4):567-71. doi: 10.1111/j.1365-2125.1984.tb02505.x.
Ten healthy male volunteers were given 200 mg p.o. of isoxicam after an overnight fast and the plasma concentrations over time followed for 96 h by h.p.l.c. Five days later enteric coated acetylsalicylic acid (ASA) 650 mg four times daily was started and continued for 10 days producing steady state trough plasma salicylate of 83 mg/l (range 21-133). A second 200 mg isoxicam dose was given 5 days after starting ASA and the plasma concentration time-curve again followed. After ASA, there was no change in lag time (0.54 vs 0.51 h), time to peak concentration (10 vs 10 h), or disappearance t1/2 (28.7 vs 31.0 h) however the peak isoxicam concentration and AUC were reduced 18 and 22% respectively (P less than 0.01). Plasma protein binding of isoxicam studied by equilibrium dialysis was 96 +/- 1% in the absence and 86 +/- 5% in the presence of ASA. The reduction in binding was unrelated to plasma SA concentrations achieved or observed reductions in AUC for plasma isoxicam. ASA decreased plasma isoxicam binding, peak plasma isoxicam concentrations and AUC without altering the apparent disappearance half-life of total plasma isoxicam after a single oral dose.
十名健康男性志愿者在禁食过夜后口服200毫克异恶酰胺,然后通过高效液相色谱法跟踪96小时内的血浆浓度变化。五天后,开始每日四次服用650毫克肠溶阿司匹林(ASA),并持续10天,使血浆水杨酸稳态谷浓度达到83毫克/升(范围为21 - 133)。在开始服用ASA五天后,再次给予200毫克异恶酰胺剂量,并再次跟踪血浆浓度-时间曲线。服用ASA后,滞后时间(0.54对0.51小时)、达峰时间(10对10小时)或消除半衰期(28.7对31.0小时)均无变化,然而异恶酰胺的峰浓度和曲线下面积(AUC)分别降低了18%和22%(P小于0.01)。通过平衡透析研究,在不存在ASA时异恶酰胺的血浆蛋白结合率为96±1%,在存在ASA时为86±5%。结合率的降低与所达到的血浆水杨酸浓度或观察到的血浆异恶酰胺AUC降低无关。ASA降低了血浆异恶酰胺结合率、血浆异恶酰胺峰浓度和AUC,而单次口服剂量后总血浆异恶酰胺的表观消除半衰期未改变。